Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China

Objective: EMPEROR-Reduced and EMPEROR-Preserved studies showed the benefits of empagliflozin along with a reduction in cardiovascular death or hospitalisation for heart failure (HF). Our aim was to evaluate the economics and effectiveness of adding empagliflozin to the standard therapy for HF with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yi, Sang, Haiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649680/
https://www.ncbi.nlm.nih.gov/pubmed/36386229
http://dx.doi.org/10.3389/fphar.2022.1030642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649680/
https://www.ncbi.nlm.nih.gov/pubmed/36386229
http://dx.doi.org/10.3389/fphar.2022.1030642

Ejemplares similares